Phospholipases A2 in normal human conjunctiva and from patients with primary open-angle glaucoma and exfoliation glaucoma

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 5, 2008, Pages 739-746

  Helin, Minna ^a   Rönkkö, Seppo ^a   Puustjärvi, Tuomo ^b   Teräsvirta, Markku ^a,b   Uusitalo, Hannu ^a,b,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Deep sclerectomy; Inflammation; Ocular surface; Topical medication

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; MEMBRANE PHOSPHOLIPID; MIOTIC AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN DERIVATIVE; ANTIHYPERTENSIVE AGENT; CYTOSOLIC PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP V; PHOSPHOLIPASE A2 GROUP VI; PLA2G5 PROTEIN, HUMAN; PLA2G6 PROTEIN, HUMAN; SECRETORY PHOSPHOLIPASE A2;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVA EPITHELIUM; CONJUNCTIVAL BIOPSY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXFOLIATION SYNDROME; EYE PROTECTION; FILTERING OPERATION; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MECHANICAL STRESS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; SCAR FORMATION; SCLERECTOMY; CONJUNCTIVA; ENZYME IMMUNOASSAY; ENZYMOLOGY; GLAUCOMA SURGERY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CONJUNCTIVA; EXFOLIATION SYNDROME; GLAUCOMA, OPEN-ANGLE; GROUP II PHOSPHOLIPASES A2; GROUP V PHOSPHOLIPASES A2; GROUP VI PHOSPHOLIPASES A2; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PHOSPHOLIPASES A2; PHOSPHOLIPASES A2, CYTOSOLIC; PHOSPHOLIPASES A2, SECRETORY; SCLEROSTOMY;

EID: 42049101402     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-007-0757-4     Document Type: Article

References (48)

1. Dennis EA (1983) Phospholipases. In: Boyer P (eds) The enzymes, vol. XVI. Academic Press, New York, pp 307-351
2. 2. J Biol Chem 269:3057-13060
3. 2s in cell injury and death. J Pharmacol Exp Ther 294:793-799
4. 2 field. Biol Pharm Bull 27:1179-1182
5. 2 and apoptosis. Biochem Biophys Acta 1585:72-76
6. 2: A major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall. J Biol Chem 277:1788-1793
7. 2 in rat chondrocyte via its specific binding sites. Biochem Biophys Res Commun 186:1025-1031
8. 2-induced stimulation of A549 lung adenocarcinoma cell line proliferation. Biochim Biophys Acta 1164:236-242
9. 2. Rev Physiol Biochem Pharmacol 91:91-203
10. 2 in eicosanoid generation. Am J Respir Crit Care Med 161:S32-S35
11. 2. J Biol Chem 273:14411-14423
12. 2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 274:3103-3115
13. 2 induces vascular endothelial cell migration. Blood 96:3809-3815
14. 2 in the central nervous system: Implications for neurodegenerative diseases. J Lipid Res 45:205-213
15. 2 in serum and ascitic exudate in experimental acute haemorrhagic pancreatitis in pigs. Eur Surg Res 11:172-178
16. 2 in acute pancreatitis: An experimental study in rats. Gut 40:386-392
17. 2 in vascular disease. Circ Res 89:298-304
18. 2 in synovial fluid and serum in acute arthritis. Scand J Rheumatol 23:68-72
19. Lee DA, Higginbotham EJ (2005) Glaucoma and its treatment: A review. Am J Health Syst Pharm 62:691-699
20. Marquis RE, Whitson JT (2005) Management of glaucoma: Focus on pharmacological therapy. Drugs Aging 22:1-21
21. Weinreb RN, Khaw PT (2004) Primary open-angle glaucoma. Lancet 363:1711-1720
22. Brandt JD, Wittpenn JR, Katz LJ, Steinmann WN, Spaeth GL (1991) Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol 112:97-301
23. Nenciu A, Stefan C, Ardelean C (2004) Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication. Oftalmologia 48:35-42
24. Baudouin C (2005) Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 5:459-463
25. Rönkkö S, Rekonen P, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H (2007) Matrix metalloproteinases and their inhibitors in chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol 245:697-704
26. Balsinde J (2002) Roles of various phospholipases A 2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. Biochem J 364:695-702
27. 2 antigen in arthritic synovium. Ann Rheum Dis 57:550-558
28. 2 IIA levels and histological activity in patients with ulcerative colitis. Int J Colorectal Dis 17:311-316
29. 2 gene expression in transcriptionally regulated in rat liver during sepsis. Am J Physiol 273:G706-G712
30. 2. Semin Cell Dev Biol 8:297-303
31. 2. J Biol Chem 264:5768-5775
32. 2 and decorin in human atherosclerotic lesions. Circ Res 86:707-714
33. 2. FEBS Lett 531:7-11
34. 2 increases atherosclerosis and enhances collagen deposition. J Lipid Res 46:201-210
35. 2 in young spontaneously hypertensive rats. J Immunol 176:7000-7007
36. Daniels JT, Occleston NL, Crowston JG, Cordeiro MF, Alexander RA, Wilkins M, Porter R, Brown R, Khaw PT (1998) Understanding and controlling the scarring response: The contribution of histology and microscopy. Microsc Res Tech 42:317-333
37. Broadway DC, Grierson I, O'Brien C, Hitchings RA (1994) Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 112:1446-1454
38. Mietz H, Schlötzer-Schrehardt U, Strassfeld C, Krieglstein GK (2001) Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. Invest Ophthalmol Vis Sci 42:679-687
39. Nuzzi R, Vercelli A, Finazzo C, Cracco C (1995) Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: An immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 233:154-162
40. 2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Bio l18:519-525
41. 2 in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. Arterioscler Thromb Vasc Biol 20:751-762
42. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F (2004) Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 111:2186-2192
43. Manni G, Centofanti M, Oddone F, Parravano M, Bucci MG (2005) Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol 139:72-77
44. Mietz H, Schlotzer-Schrehardt U, Lemke JH, Krieglstein GK (1997) Early conjunctival changes following treatment with metipranolol and preservatives are not reversible with dexamethasone. Graefes Arch Clin Exp Ophthalmol 235:452-459
45. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C (2004) Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: An ex vivo and in vitro study. Invest Ophthalmol Vis Sci 45:1360-1368
46. Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM (1992) Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 99:197-202
47. Costagliola C, Prete AD, Incorvaia C, Fusco R, Parmeggiani F, Di Giovanni A (2001) Ocular surface changes induced by topical application of latanoprost and timolol: A short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 239:809-814
48. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F (2005) In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 46:4594-4599